Epiminder Ltd (EPI) - Net Assets
Based on the latest financial reports, Epiminder Ltd (EPI) has net assets worth AU$100.27 Million AUD (≈ $70.95 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (AU$104.35 Million ≈ $73.84 Million USD) and total liabilities (AU$4.08 Million ≈ $2.89 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore Epiminder Ltd assets under control for the complete picture of this company's asset base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | AU$100.27 Million |
| % of Total Assets | 96.09% |
| Annual Growth Rate | 777.1% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Epiminder Ltd - Net Assets Trend (2023–2025)
This chart illustrates how Epiminder Ltd's net assets have evolved over time, based on quarterly financial data. Check EPI tangible net assets ratio to evaluate the tangible quality of the company's equity base.
Annual Net Assets for Epiminder Ltd (2023–2025)
The table below shows the annual net assets of Epiminder Ltd from 2023 to 2025. For live valuation and market cap data, see how much is Epiminder Ltd worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-06-30 | AU$107.39 Million ≈ $75.98 Million |
+1477.91% |
| 2024-06-30 | AU$-7.79 Million ≈ $-5.51 Million |
-659.98% |
| 2023-06-30 | AU$1.39 Million ≈ $984.74K |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Epiminder Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 8046160000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (June 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | AU$37.22 Million | 34.66% |
| Other Components | AU$180.90 Million | 168.46% |
| Total Equity | AU$107.39 Million | 100.00% |
Epiminder Ltd Competitors by Market Cap
The table below lists competitors of Epiminder Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
EARNZ plc
LSE:EARN
|
$52.95K |
|
Sporttotal AG
F:WIG1
|
$53.14K |
|
Mercantile Ports & Logistics Ltd
LSE:MPL
|
$54.19K |
|
Selina Hospitality PLC
NASDAQ:SLNAF
|
$54.37K |
|
Sound Energy PLC
LSE:SOU
|
$52.79K |
|
Oxford Biodynamics PLC
LSE:OBD
|
$52.21K |
|
Empyrean Energy Plc
LSE:EME
|
$52.19K |
|
Brighton Pier Group PLC
LSE:PIER
|
$52.17K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Epiminder Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -7,793,360 to 107,385,422, a change of 115,178,782.
- Net loss of 31,778,980 reduced equity.
- Other factors increased equity by 146,957,762.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | AU$-31.78 Million | -29.59% |
| Other Changes | AU$146.96 Million | +136.85% |
| Total Change | AU$- | % |
Book Value vs Market Value Analysis
This analysis compares Epiminder Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.56x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 53.71x to 0.56x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2023-06-30 | AU$0.01 | AU$0.35 | x |
| 2024-06-30 | AU$-0.04 | AU$0.35 | x |
| 2025-06-30 | AU$0.61 | AU$0.35 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Epiminder Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -29.59%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -7138.46%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.22x
- Recent ROE (-29.59%) is above the historical average (-394.98%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2023 | -1155.36% | -292.72% | 0.15x | 26.28x | AU$-16.22 Million |
| 2024 | 0.00% | -242.54% | 0.19x | 0.00x | AU$-15.14 Million |
| 2025 | -29.59% | -7138.46% | 0.00x | 1.22x | AU$-42.52 Million |
Industry Comparison
This section compares Epiminder Ltd's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $67,903,126
- Average return on equity (ROE) among peers: -47.67%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Epiminder Ltd (EPI) | AU$100.27 Million | -1155.36% | 0.04x | $52.89K |
| 4DMEDICAL Ltd (4DX) | $-11.81 Million | 0.00% | 0.00x | $1.61 Billion |
| Adherium Ltd (ADR) | $94.00K | 0.00% | 1.11x | $10.75 Million |
| Aroa Biosurgery Ltd (ARX) | $1.77 Million | -66.67% | 7.09x | $144.76 Million |
| Atomo Diagnostics Ltd (AT1) | $24.81 Million | -23.00% | 0.07x | $10.84 Million |
| Avita Medical Inc (AVH) | $20.86 Million | -118.03% | 0.23x | $134.47 Million |
| Anteris Technologies Global Corp (AVR) | $28.66 Million | -234.92% | 0.59x | $848.00 Million |
| Control Bionics Ltd (CBL) | $148.55 Million | 0.00% | 2.92x | $22.82 Million |
| Cardiex Ltd (CDX) | $5.96 Million | -63.62% | 0.33x | $13.23 Million |
| Compumedics Ltd (CMP) | $21.82 Million | -5.83% | 1.49x | $32.51 Million |
| Cochlear Ltd (COH) | $438.31 Million | 35.40% | 0.72x | $5.63 Billion |
About Epiminder Ltd
Epiminder Limited develops and manufactures a monitoring device to improve treatment of patients suffering with epileptic seizures and related conditions. It offers Minder system, an implantable sub scalp electroencephalography (EEG) monitoring system which is designed for continuous monitoring of brain activity. The company's Minder system comprises Minder implant, a sub scalp electrode with mul… Read more